The global lifestyle drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of lifestyle diseases and growing awareness about the benefits of lifestyle drugs among consumers.
The global lifestyle drugs market is segmented on the basis of type, application, and region. On the basis of type, it is classified into depression, dermatology, sexual dysfunction and obesity. On the basis of application, it is classified into children (0-12 years), adults (13-64 years) and senior citizens (>65 years). On the basis of region it includes North America (US & Canada), Latin America (Mexico & Brazil), Europe (UK & Germany), Asia Pacific (China & Japan) and Middle East & Africa (Saudi Arabia).
Some Of The Growth Factors Of This Market:
- The increase in the number of people suffering from chronic diseases such as diabetes, obesity, and heart disease.
- The aging population.
- The increase in the number of people with sedentary lifestyles.
- The increased use of prescription drugs for mental health disorders.
- Increased awareness about lifestyle drugs.
Industry Growth Insights published a new data on “Lifestyle Drugs Market”. The research report is titled “Lifestyle Drugs Market research by Types (Depression, Dermatology, Sexual dysfunction, Obesity), By Applications (Children, Adults, Senior Citizens), By Players/Companies Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, Cosmo Pharmaceuticals, CTC Bio, Dermira, Dong-A ST, Euthymics Bioscience, Foamix, Follicum, Forendo Pharma, Futura Medical Developments, Galderma”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lifestyle Drugs Market Research Report
By Type
Depression, Dermatology, Sexual dysfunction, Obesity
By Application
Children, Adults, Senior Citizens
By Companies
Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, Cosmo Pharmaceuticals, CTC Bio, Dermira, Dong-A ST, Euthymics Bioscience, Foamix, Follicum, Forendo Pharma, Futura Medical Developments, Galderma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
238
Number of Tables & Figures
167
Customization Available
Yes, the report can be customized as per your need.
Global Lifestyle Drugs Market Report Segments:
The global Lifestyle Drugs market is segmented on the basis of:
Types
Depression, Dermatology, Sexual dysfunction, Obesity
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Children, Adults, Senior Citizens
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Allergan
- BMS
- Eli Lilly
- Pfizer
- Acerus Pharmaceuticals
- Alkermes
- Amorepacific
- AndroScience
- Anterios
- AstraZeneca
- Avanir Pharmaceuticals
- Avolynt
- Celtaxsys
- Cerecor
- Corcept Therapeutics
- Cosmo Pharmaceuticals
- CTC Bio
- Dermira
- Dong-A ST
- Euthymics Bioscience
- Foamix
- Follicum
- Forendo Pharma
- Futura Medical Developments
- Galderma
Highlights of The Lifestyle Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Depression
- Dermatology
- Sexual dysfunction
- Obesity
- By Application:
- Children
- Adults
- Senior Citizens
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lifestyle Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lifestyle drugs are drugs that people use to alter their behavior or lifestyle. These drugs can be used for a variety of reasons, such as reducing stress, improving moods, or increasing energy levels.
Some of the major players in the lifestyle drugs market are Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, Cosmo Pharmaceuticals, CTC Bio, Dermira, Dong-A ST, Euthymics Bioscience, Foamix, Follicum, Forendo Pharma, Futura Medical Developments, Galderma.
The lifestyle drugs market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Lifestyle Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Lifestyle Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Lifestyle Drugs Market - Supply Chain
4.5. Global Lifestyle Drugs Market Forecast
4.5.1. Lifestyle Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Lifestyle Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Lifestyle Drugs Market Absolute $ Opportunity
5. Global Lifestyle Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Lifestyle Drugs Market Size and Volume Forecast by Type
5.3.1. Depression
5.3.2. Dermatology
5.3.3. Sexual dysfunction
5.3.4. Obesity
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Lifestyle Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Lifestyle Drugs Market Size and Volume Forecast by Application
6.3.1. Children
6.3.2. Adults
6.3.3. Senior Citizens
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Lifestyle Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Lifestyle Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Lifestyle Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Lifestyle Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Lifestyle Drugs Demand Share Forecast, 2019-2029
9. North America Lifestyle Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Lifestyle Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Lifestyle Drugs Market Size and Volume Forecast by Application
9.4.1. Children
9.4.2. Adults
9.4.3. Senior Citizens
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Lifestyle Drugs Market Size and Volume Forecast by Type
9.7.1. Depression
9.7.2. Dermatology
9.7.3. Sexual dysfunction
9.7.4. Obesity
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Lifestyle Drugs Demand Share Forecast, 2019-2029
10. Latin America Lifestyle Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Lifestyle Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Lifestyle Drugs Market Size and Volume Forecast by Application
10.4.1. Children
10.4.2. Adults
10.4.3. Senior Citizens
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Lifestyle Drugs Market Size and Volume Forecast by Type
10.7.1. Depression
10.7.2. Dermatology
10.7.3. Sexual dysfunction
10.7.4. Obesity
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Lifestyle Drugs Demand Share Forecast, 2019-2029
11. Europe Lifestyle Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Lifestyle Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Lifestyle Drugs Market Size and Volume Forecast by Application
11.4.1. Children
11.4.2. Adults
11.4.3. Senior Citizens
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Lifestyle Drugs Market Size and Volume Forecast by Type
11.7.1. Depression
11.7.2. Dermatology
11.7.3. Sexual dysfunction
11.7.4. Obesity
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Lifestyle Drugs Demand Share, 2019-2029
12. Asia Pacific Lifestyle Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Lifestyle Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Lifestyle Drugs Market Size and Volume Forecast by Application
12.4.1. Children
12.4.2. Adults
12.4.3. Senior Citizens
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Lifestyle Drugs Market Size and Volume Forecast by Type
12.7.1. Depression
12.7.2. Dermatology
12.7.3. Sexual dysfunction
12.7.4. Obesity
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Lifestyle Drugs Demand Share, 2019-2029
13. Middle East & Africa Lifestyle Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Lifestyle Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Lifestyle Drugs Market Size and Volume Forecast by Application
13.4.1. Children
13.4.2. Adults
13.4.3. Senior Citizens
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Lifestyle Drugs Market Size and Volume Forecast by Type
13.7.1. Depression
13.7.2. Dermatology
13.7.3. Sexual dysfunction
13.7.4. Obesity
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Lifestyle Drugs Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Lifestyle Drugs Market: Market Share Analysis
14.2. Lifestyle Drugs Distributors and Customers
14.3. Lifestyle Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Allergan
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. BMS
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Acerus Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Alkermes
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Amorepacific
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AndroScience
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Anterios
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. AstraZeneca
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Avanir Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Avolynt
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Celtaxsys
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Cerecor
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Corcept Therapeutics
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Cosmo Pharmaceuticals
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. CTC Bio
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Dermira
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Dong-A ST
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Euthymics Bioscience
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
